DE69728582D1 - Nichtwässrige polar-aprotische Peptidformulierungen enthaltend LHRH-verwandte Verbindungen - Google Patents

Nichtwässrige polar-aprotische Peptidformulierungen enthaltend LHRH-verwandte Verbindungen

Info

Publication number
DE69728582D1
DE69728582D1 DE69728582T DE69728582T DE69728582D1 DE 69728582 D1 DE69728582 D1 DE 69728582D1 DE 69728582 T DE69728582 T DE 69728582T DE 69728582 T DE69728582 T DE 69728582T DE 69728582 D1 DE69728582 D1 DE 69728582D1
Authority
DE
Germany
Prior art keywords
formulations containing
related compounds
polar aprotic
aqueous polar
peptide formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69728582T
Other languages
English (en)
Other versions
DE69728582T2 (de
Inventor
Cynthia L Stevenson
Steven J Prestrelski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21810971&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69728582(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of DE69728582D1 publication Critical patent/DE69728582D1/de
Application granted granted Critical
Publication of DE69728582T2 publication Critical patent/DE69728582T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/23Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
DE69728582T 1996-07-03 1997-07-01 Stabile, nichtwäßrige Formulierung einer Peptidverbindung Expired - Lifetime DE69728582T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2269996P 1996-07-03 1996-07-03
US22699P 1996-07-03

Publications (2)

Publication Number Publication Date
DE69728582D1 true DE69728582D1 (de) 2004-05-13
DE69728582T2 DE69728582T2 (de) 2004-08-19

Family

ID=21810971

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69728582T Expired - Lifetime DE69728582T2 (de) 1996-07-03 1997-07-01 Stabile, nichtwäßrige Formulierung einer Peptidverbindung
DE69715639T Expired - Lifetime DE69715639T2 (de) 1996-07-03 1997-07-01 Nicht wässrige polar-aprotische peptidzubereitung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69715639T Expired - Lifetime DE69715639T2 (de) 1996-07-03 1997-07-01 Nicht wässrige polar-aprotische peptidzubereitung

Country Status (29)

Country Link
US (3) US5932547A (de)
EP (2) EP1208846B1 (de)
JP (2) JP2000515131A (de)
CN (4) CN101239179A (de)
AR (1) AR007714A1 (de)
AT (2) ATE263570T1 (de)
AU (1) AU739169B2 (de)
BR (1) BR9710132A (de)
CA (1) CA2259557A1 (de)
CO (1) CO4870762A1 (de)
CY (1) CY2486B1 (de)
CZ (2) CZ300378B6 (de)
DE (2) DE69728582T2 (de)
DK (2) DK0921808T3 (de)
ES (2) ES2181010T3 (de)
HU (1) HUP9904270A3 (de)
ID (2) ID19718A (de)
IL (3) IL127771A0 (de)
MY (1) MY128850A (de)
NO (2) NO322514B1 (de)
NZ (1) NZ333294A (de)
PL (1) PL189015B1 (de)
PT (2) PT921808E (de)
RO (1) RO119863B1 (de)
RU (1) RU2203084C2 (de)
SK (1) SK283926B6 (de)
TW (1) TW584562B (de)
WO (1) WO1998000158A1 (de)
ZA (1) ZA975941B (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
ES2253375T3 (es) 2000-04-19 2006-06-01 Genentech, Inc. Formulaciones de liberacion sostenida.
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
EP1372729B1 (de) * 2001-02-23 2009-04-08 Genentech, Inc. Erodierbare polymere zur injektion
JP4460892B2 (ja) * 2001-06-21 2010-05-12 ジェネンテック インコーポレイテッド 徐放性組成物
EP2261250B1 (de) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin Fusionsproteine
AU2003219787A1 (en) * 2002-02-14 2003-09-04 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
MY135711A (en) * 2002-06-17 2008-06-30 Alza Corp Osmotic delivery system with early zero order push power engine
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
AU2003297464A1 (en) * 2002-12-19 2004-07-14 Alza Corporation Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
EP1589901A4 (de) 2002-12-20 2006-08-09 Generipharm Inc Intrakutane injektion
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7207982B2 (en) * 2003-03-31 2007-04-24 Alza Corporation Osmotic pump with means for dissipating internal pressure
KR20050120767A (ko) * 2003-03-31 2005-12-23 알자 코포레이션 삼투성 전달 시스템 및 삼투성 전달 시스템의 기동 시간감소 방법
WO2004096176A2 (en) * 2003-04-25 2004-11-11 Boston Scientific Scimed Inc. Solid drug formulation and device for storage and controlled delivery thereof
ES2425221T3 (es) * 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
EP1686968A2 (de) * 2003-10-31 2006-08-09 Alza Corporation Osmotische pumpe mit selbsthaltendem schnellstart-membranstopfen
MXPA06003065A (es) * 2003-11-06 2006-05-31 Alza Corp Reductor de velocidad de imbibicion modular para uso con bomba osmotica implantable.
FI116942B (fi) * 2004-05-10 2006-04-13 Biohit Oyj Proteiini- ja peptidistabilointi
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
US20060057184A1 (en) * 2004-09-16 2006-03-16 Nycz Jeffrey H Process to treat avascular necrosis (AVN) with osteoinductive materials
US8137664B2 (en) * 2005-02-02 2012-03-20 Sdgi Holdings, Inc. Method and kit for repairing a defect in bone
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006084141A2 (en) * 2005-02-03 2006-08-10 Intarcia Therapeutics, Inc Suspension formulation of interferon
WO2006083761A2 (en) * 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US7959938B2 (en) * 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
WO2006110551A2 (en) * 2005-04-08 2006-10-19 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
JP5276448B2 (ja) * 2005-12-22 2013-08-28 オークウッド ラボラトリーズ,エル.エル.シー. 昇華可能な持続放出デリバリーシステム及びその製造方法
CN105232482A (zh) * 2006-04-07 2016-01-13 默里昂研究Iii有限公司 包含增强剂的固体口服剂型
NZ572003A (en) * 2006-05-30 2010-07-30 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator with spiral fluid channel
EP2040731A4 (de) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd Feste orale dosierform mit einem verstärkungsmittel
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
NZ580447A (en) 2007-04-23 2011-06-30 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
ES2717154T3 (es) 2007-06-22 2019-06-19 Univ Texas Formación de partículas de péptido o proteína submicrométricas estables mediante congelación de película fina
WO2009033663A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of fertirelin and delta-endorphin as therapeutic agents
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
AU2009244797B2 (en) * 2008-05-07 2015-01-22 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
US20100015240A1 (en) * 2008-07-16 2010-01-21 Danielle Biggs Process for preparing microparticles containing bioactive peptides
KR101704832B1 (ko) 2008-08-15 2017-02-08 아이언우드 파마슈티컬스, 인코포레이티드 경구 투여를 위한 리나클로타이드-함유 제형
EP2161030A1 (de) * 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytozinformulierungen und ihre Verwendungen
CN106880596A (zh) * 2008-10-15 2017-06-23 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用
US8779094B2 (en) 2008-11-16 2014-07-15 Board Of Regents, The University Of Texas System Low viscosity highly concentrated suspensions
EP2400851A4 (de) * 2009-02-25 2012-09-05 Merrion Res Iii Ltd Zusammensetzung und wirkstofffreisetzung von bisphosphonaten
MX2012001660A (es) 2009-08-06 2012-03-26 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para adminstracion oral.
NZ624569A (en) 2009-09-28 2016-01-29 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
PL2536742T3 (pl) 2010-02-17 2017-11-30 Ironwood Pharmaceuticals, Inc. Leczenie zaburzeń żołądkowo-jelitowych
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
ES2919136T3 (es) 2010-08-11 2022-07-22 Ironwood Pharmaceuticals Inc Formulaciones estables de linaclotida
JP2014501784A (ja) 2011-01-07 2014-01-23 メリオン・リサーチ・Iii・リミテッド 経口投与用の鉄の医薬組成物
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR101978527B1 (ko) * 2011-03-10 2019-09-03 엑스에리스 파머수티클스, 인크. 펩티드 약물의 비경구 주입을 위한 안정한 제형
HUE032237T2 (en) 2011-08-17 2017-09-28 Ironwood Pharmaceuticals Inc Treatment of gastrointestinal disorders
AU2012332556B2 (en) * 2011-10-31 2016-05-26 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
US9207513B2 (en) 2012-04-10 2015-12-08 The Regents Of The University Of California Nanocrystal-polymer nanocomposite electrochromic device
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
WO2015120231A2 (en) * 2014-02-06 2015-08-13 Xeris Phrmaceuticals, Inc. Stable peptide formulations and methods for preparation
US11129940B2 (en) 2014-08-06 2021-09-28 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
MX2017015504A (es) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Sistemas de colocacion y remoción de implante.
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
SG11201810102SA (en) 2016-05-16 2018-12-28 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
IL307966A (en) 2017-01-03 2023-12-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
AU2018275686B2 (en) 2017-06-02 2024-02-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
TW202304501A (zh) 2017-08-24 2023-02-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
EP4106727A1 (de) 2020-02-18 2022-12-28 Novo Nordisk A/S Pharmazeutische formulierungen

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL22493A (en) * 1963-12-09 1968-10-24 Crown Zellerbach Corp Membrane penetrant composition containing a dialkyl sulfoxide
US3914412A (en) * 1973-10-11 1975-10-21 Abbott Lab {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity
GB2008403B (en) * 1977-11-04 1982-07-28 Christie R B Parsons J A Pharmaceutical compositions
GB2119248A (en) * 1982-04-28 1983-11-16 John Kenneth Mcmullen Insulin formulations and method of producing them
US4547370A (en) * 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US4661472A (en) * 1985-05-09 1987-04-28 The Salk Institute For Biological Studies GnRH antagonists IX
US4897256A (en) * 1986-11-25 1990-01-30 Abbott Laboratories LHRH analog formulations
US4851385A (en) * 1987-07-15 1989-07-25 Indiana University Foundation LHRH antagonist analogs having low histamine-release activity
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
EP0312052B1 (de) * 1987-10-15 1994-01-05 Syntex (U.S.A.) Inc. Pulverförmige Zubereitungen zur intranasalen Verabreichung von Polypeptiden
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
DE4117507A1 (de) * 1991-05-24 1992-11-26 Schering Ag Verfahren zur herstellung von n(pfeil hoch)6(pfeil hoch)-substituierten lysin-derivaten
DK0661989T3 (da) * 1992-09-21 1998-03-02 Upjohn Co Proteinsammensætninger med vedvarende frigivelse
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
ES2153418T3 (es) * 1993-02-23 2001-03-01 Genentech Inc Estabilizacion de polipeptidos tratados con solventes organicos por medio de excipientes.
DE4320201A1 (de) * 1993-06-18 1995-01-12 Asta Medica Ag Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
US5413990A (en) * 1993-08-06 1995-05-09 Tap Pharmaceuticals Inc. N-terminus modified analogs of LHRH
DK1238657T3 (da) * 1996-02-02 2005-01-17 Alza Corp Vedvarende frigivelse af et aktivt middel ved anvendelse af et implanterbart system
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations

Also Published As

Publication number Publication date
HUP9904270A2 (hu) 2000-05-28
CZ434098A3 (cs) 1999-04-14
NO986207L (no) 1999-03-03
CN1636589A (zh) 2005-07-13
US6124261A (en) 2000-09-26
NZ333294A (en) 2000-05-26
CN101116742A (zh) 2008-02-06
DE69715639D1 (de) 2002-10-24
MY128850A (en) 2007-02-28
RU2203084C2 (ru) 2003-04-27
PL330927A1 (en) 1999-06-07
JP2009073852A (ja) 2009-04-09
BR9710132A (pt) 1999-08-10
ES2215967T3 (es) 2004-10-16
ID28822A (id) 1998-01-08
RO119863B1 (ro) 2005-05-30
ATE263570T1 (de) 2004-04-15
CN102512658A (zh) 2012-06-27
EP1208846A3 (de) 2003-04-16
CO4870762A1 (es) 1999-12-27
SK283926B6 (sk) 2004-05-04
PT1208846E (pt) 2004-06-30
EP0921808B1 (de) 2002-09-18
WO1998000158A1 (en) 1998-01-08
EP0921808A1 (de) 1999-06-16
ATE224199T1 (de) 2002-10-15
NO986207D0 (no) 1998-12-30
DK1208846T3 (da) 2004-08-02
TW584562B (en) 2004-04-21
EP1208846B1 (de) 2004-04-07
ES2181010T3 (es) 2003-02-16
DK0921808T3 (da) 2003-01-27
US5932547A (en) 1999-08-03
AU3587997A (en) 1998-01-21
US6235712B1 (en) 2001-05-22
PT921808E (pt) 2003-01-31
PL189015B1 (pl) 2005-06-30
JP2000515131A (ja) 2000-11-14
IL178824A0 (en) 2007-03-08
IL170958A (en) 2009-11-18
IL178824A (en) 2011-08-31
AU739169B2 (en) 2001-10-04
IL127771A0 (en) 1999-10-28
DE69715639T2 (de) 2003-02-06
ZA975941B (en) 1998-04-16
NO20063870L (no) 1999-03-03
CN101239179A (zh) 2008-08-13
CZ300378B6 (cs) 2009-05-06
NO322514B1 (no) 2006-10-16
HUP9904270A3 (en) 2001-08-28
CY2486B1 (en) 2005-06-03
AR007714A1 (es) 1999-11-10
DE69728582T2 (de) 2004-08-19
CA2259557A1 (en) 1998-01-08
SK179798A3 (en) 1999-05-07
CZ299464B6 (cs) 2008-08-06
ID19718A (id) 1998-07-30
EP1208846A2 (de) 2002-05-29

Similar Documents

Publication Publication Date Title
DE69728582D1 (de) Nichtwässrige polar-aprotische Peptidformulierungen enthaltend LHRH-verwandte Verbindungen
NO986209L (no) Ikke-vandige protiske peptidformuleringer
AU1602100A (en) Improved gamma amino butyric acid analogs
IS5555A (is) Selekoxib lyfjablöndur
NO20004240L (no) Formuleringer
CY2006006I1 (el) Πρωτεϊνικα σκευασματα
ATE224703T1 (de) Brauseformulierungen
PT946100E (pt) Composicoes herbicidas contendo n-¬(4,6-dimetoxipirimidin-2-il)aminocarbonil|-5-metilsulfonamidometil-2-alcoxicarbonilbenzenossulfonamidas
ATE288201T1 (de) Antiparasitäre formulierungen
DE69823808D1 (de) Abbildungs-spektrometer
EE03832B1 (et) Heptapeptiidanaloogid
PT988861E (pt) Formulacoes de proteina estabilizadas
DE69935609D1 (de) Formulierungen enthaltend cefuroxim-axetil
BR9704422A (pt) Composto de borracha contendo aminobenzilamina
NO20013020L (no) Immunsuppresjon
GB9806312D0 (en) Novel formulations
ATE258011T1 (de) Benetzbare pulverformulierungen
DE29721440U1 (de) NH-Lasttrennschalter
NO20012283D0 (no) Koblede peptider
GB9810181D0 (en) Novel formulations
IT1283641B1 (it) Procedimento per la preparazione di cefalosporine
DE29615003U1 (de) Lolly (Lutscher)
SE9802536D0 (sv) Novel peptides

Legal Events

Date Code Title Description
8364 No opposition during term of opposition